VYNE Therapeutics Inc. - VYNE STOCK NEWS

VYNE Therapeutics Inc. announced that CEO David Domzalski will present at the Cowen 41st Annual Health Care Conference on March 2, 2021, at 2:10 PM ET. The presentation will be in a fireside chat format, providing insights into the company's innovative therapies in dermatology, including AMZEEQ® and ZILXI®, both FDA-approved minocycline products. For those interested, the webcast link is here. VYNE aims to enhance the lives of patients through proprietary therapies.

VYNE Therapeutics announced promising preclinical data for FMX114, a topical gel designed to treat mild-to-moderate atopic dermatitis (AD). The Phase 2a clinical study is set to begin in the third quarter of 2021, with top-line results expected by year-end. In animal studies, FMX114 demonstrated an 89% reduction in the modified atopic dermatitis index score compared to control. VYNE plans to discuss further details during the year-end earnings call on March 4, 2021.

VYNE Therapeutics Inc. (Nasdaq: VYNE) will report its financial results for the year ended December 31, 2020, on March 4, 2021, before market opening. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. VYNE focuses on developing innovative dermatological therapies and has FDA approval for AMZEEQ and ZILXI, both minocycline topical products for acne and rosacea, respectively. This announcement indicates VYNE's ongoing commitment to transparency and communication with investors.

VYNE Therapeutics has announced a 1-for-4 reverse stock split effective February 16, 2021, to consolidate its shares from approximately 205 million to about 51 million. This move aims to align its share count with companies of similar market capitalizations. Stockholders will receive cash for any fractional shares following the split. The reverse stock split was earlier approved by stockholders at the Annual Meeting on August 3, 2020. The company's trading symbol will remain VYNE, and the new CUSIP number will be 92941V 209.

VYNE Therapeutics announced FDA approval for a label update of AMZEEQ® (minocycline) topical foam, which confirms a low propensity for P. acnes to develop resistance to minocycline. This update is significant for treating inflammatory lesions of moderate to severe acne in patients aged 9 and older. The label states spontaneous mutation frequencies for resistance are less than 1 in 100 million. CEO David Domzalski emphasized this information aids dermatologists in antibiotic choices, while the update is backed by a comprehensive antimicrobial characterization program.

VYNE Therapeutics has completed a registered direct offering of 21,097,046 shares of common stock at $2.37 per share, raising approximately $46.7 million in net proceeds. These funds will be used for working capital and general corporate purposes. Previously, VYNE raised an additional $34.3 million via an at-the-market program, bringing total net proceeds to $81.0 million. The company anticipates this cash influx will cover its operational and capital needs through the end of 2022, allowing for the termination of its at-the-market program.

VYNE Therapeutics Inc. (Nasdaq: VYNE) has announced a registered direct offering of 21,097,046 shares at $2.37 per share, expected to yield approximately $50 million in gross proceeds. This offering is set to close around January 28, 2021, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. Proceeds will be used for working capital and general corporate purposes. The shares are offered under an effective registration statement.

VYNE Therapeutics (Nasdaq: VYNE) has secured a contract with a major U.S. pharmacy benefit manager (PBM) for its topical foams AMZEEQ (minocycline) 4% and ZILXI (minocycline) 1.5%. AMZEEQ is FDA-approved for treating severe acne, while ZILXI targets inflammatory lesions of rosacea. This contract signifies a major milestone, granting access to millions of covered lives and aligning with VYNE's objective to enhance commercial coverage. Both products utilize VYNE's Molecule Stabilizing Technology, offering new avenues for treating these skin conditions.

VYNE Therapeutics Inc. (Nasdaq: VYNE) has announced that CEO David Domzalski will participate in two panel discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event. The first panel, titled Dermatology Innovation: Addressing Physician and Patient Underserved Needs, is scheduled for January 7 at 2:00 PM ET, followed by Executing a Successful Product Launch During a Pandemic on January 8 at the same time. Virtual Q&A will follow both sessions. For more details, visit the event's registration links.